Alerta

IODIDE NANOPARTICLES AND COMPOSITIONS OF METHODS OF USE THEREOF

Resumen de: US2025135050A1

Iodide nanoparticles are provided. The nanoparticles can be potassium iodide (KI) nanoparticles, and can be formed of, a radioisotope, preferably 131I or 125I. The nanoparticles can include a coating that can increase the half-life of the particles, serve as a platform for attachment or entrapment of targeting moieties and/or additional active agents, or a combination thereof. Methods of use are also provided. For example, a method of treating a subject for cancer can including sensitizing the subject to radiation therapy by administrating the iodide nanoparticles to the subject in combination with one or more doses of radiation therapy. Methods of treating or imaging a subject can also include administering the subject an effective amount iodide nanoparticles, without the nanoparticles serving as radiosensitizer. In such methods, the nanoparticles typically include a radioisotope or an anticancer active agent, for example 131I, 125I, 124I, or 123I, or a chemotherapeutic agent.

USE OF NOVEL POLYMER FOR PREVENTING SARS-COV-2

Resumen de: US2025134989A1

The present invention relates to a novel vaccine composition for coronavirus infection-19 comprising a polymer-based mRNA carrier. Specifically, the present invention provides a vaccine composition comprising an mRNA carrier using a novel polymer capable of delivering a negatively charged genetic material such as mRNA, and the vaccine composition has excellent effects of enhanced in vivo immune activity such as high antibody formation ability and increased interferon-gamma production.

STABILIZED LIPID NANOPARTICLE MRNA COMPOSITIONS AND USES THEREOF

Resumen de: US2025134986A1

Provided herein are, inter alia, compositions or formulations comprising a nucleic acid (e.g. a RNA molecule) encapsulated in a lipid nanoparticle (LNP) and their uses.

IMMUNOGENIC MRNA DELIVERY VEHICLES

Resumen de: US2025134994A1

The present disclosure relates to lipid-based delivery vehicles for mRNA vaccines, which include a lysophosphatidylcholine (LPC) compound for enhancing vaccine immunogenicity. The present disclosure also relates to methods for use of the mRNA vaccines.

BIOSYNTHETIC HEMOSTAT AND USES THEREOF

Resumen de: US2025134969A1

A biosynthetic hemostat includes a plurality of biocompatible flexible nanoparticles wherein each nanoparticle includes a shell that defines an outer surface of the nanoparticle and a core, which is loaded with thrombin, and a plurality of von Willebrand factor-binding peptides (VBPs) and collagen-binding peptides (CBPs) that are linked to the shell and extend from the outer surface.

TUNABLE POLYMERIC NANOPARTICLES FOR TARGETED AND SUSTAINED DELIVERY OF GLYCOPEPTIDE ANTIBIOTICS

Resumen de: US2025135028A1

The present disclosure provides copolymers and glycopeptide antibiotic-loaded polymeric nanoparticles (PNPs) comprising the copolymers as well as charge neutral polymers for targeted and sustained delivery of glycopeptide antibiotics to treat bacterial infections, including but not limited to biofilm bacterial infections. The copolymers are block, alternate, or random copolymers comprising x units of the formulaand y units of the formulawherein Z is an organic moiety, R and R′ are each independently selected from the group consisting of hydrogen and C1-C18 alkyl, each of x and y is an integer of 1 or greater, the sum of x and y is an integer from about 40 to about 714, and y is from about 10% to about 90% of the sum of x and y.

SPLICING MODULATOR ANTIBODY-DRUG CONJUGATES AND METHODS OF USE

Resumen de: US2025135017A1

Linker-drug compounds and antibody-drug conjugates that bind to human oncology targets are disclosed. The linker-drug compounds and antibody-drug conjugates comprise a splicing modulator drug moiety. The disclosure further relates to methods and compositions for use in the treatment of neoplastic disorders by administering the antibody-drug conjugates provided herein.

BEADS FOR TARGETED SIGNAL DELIVERY

Resumen de: US2025135027A1

Disclosed herein are cell-targeting complexes that are coated on the surface with target specific antibodies for induction of biological stimulus in target cells/tissue/organs. In some embodiments, the cell-targeting complex involves nonnucleated (e.g. platelets, red blood cells (RBC)) or enucleated cells that have been thiolated, streptavidinylated, and then coated with biotinylated antibodies. In some embodiments, the cell-targeting complex involves multilayer alginate hydrogel beads that have been coated with polyanionic proteins using a polycation, which is then thiolated, streptavidinylated, and then coated with biotinylated antibodies.

BEADED NONWOVEN MEMBRANE AS A DRUG DELIVERY SYSTEM

Resumen de: US2025134827A1

It relates to a beaded nonwoven membrane comprising polymeric nanofibers and at least one active agent, wherein the active agent has a water solubility equal to or lower than 33 mg/mL. It also relates to a process for the preparation of the beaded nonwoven membrane, and to its use in medical, and veterinary applications.

METHOD FOR PRODUCING MEDICATIONS AND VACCINES

Resumen de: US2025134825A1

The present invention relates to a method for producing a preferably lipid-based carrier system as well as to a corresponding carrier system, in addition to a composition or corresponding medicament based thereon, as well as to corresponding uses of the composition or medicant.

ANTI-COAGULATING HYDROGEL NANOFILM FOR CELL ENCAPSULATION

Resumen de: US2025134823A1

The present invention relates to a method for modifying and cross-linking an anticoagulating hydrogel nanofilm for cell encapsulation. According to the present invention, the protection from the external environment and the control of material transfer can be improved due to the anticoagulant functionalization of the material surface. In addition, when applied into the body, it can prevent fibrosis, blood coagulation, protein adsorption, and platelet adhesion caused by immune responses, thereby preventing a decrease in cell viability caused by immune responses and improving cell survival rate.

LOW-DOSE LYOPHILIZED RNA VACCINES AND METHODS FOR PREPARING AND USING THE SAME

Resumen de: US2025134824A1

Compositions and methods are provided for stabilization of RNA encapsulated by lipid nanoparticles during lyophilization. The compositions and methods involve the use of empty lipid nanoparticles to stabilize the lyophilized composition. These techniques may be used to prevent the need for cold chain storage and may also simplify the procedure at the clinic for reconstituting the vaccine to prepare an injectable composition.

NANOPARTICLE SURFACE TOPOGRAPHY MODIFIED WITH BOTTLEBRUSH BLOCK COPOLYMERS

Resumen de: US2025134822A1

A method to precisely tailor the surface topography of polymeric nanoparticles having bound thereto polyalkylene oxide, based on tuning the architecture of shape-persistent amphiphilic bottlebrush block copolymer (BBCP) building blocks, has been developed. It was demonstrated that nanoparticle formation and surface topography can be controlled by systematically changing structural parameters of BBCP architecture. The surface topography of PEGylated nanoparticles (nanoparticles having PEO or PEG covalently bound thereto) significantly affects their biological performance.

COMPOSITIONS COMPRISING A BIOABSORBABLE POLYMER AND METABOLIC INHIBITOR

Resumen de: US2025135072A1

Disclosed herein are compositions comprising a polymer and a metabolic inhibitor, as well as a method of using the composition to modulate an immune response. The composition may be produced in the form of a synthetic tissue for provision in a subject. The composition or synthetic tissue may further comprise additional therapeutic agents.

PLANT TISSUE-DERIVED NANOFIBRES

Resumen de: US2025137169A1

Provided herein are nanofibres including self-assembled cellular components derived from a homogenized plant tissue. Methods for preparing such nanofibres, as well as uses thereof in the treatment or prevention of diseases or disorders in a subject and/or as delivery vehicles are also described.

Composition

Resumen de: AU2025202623A1

The present invention provides a pharmaceutical composition comprising a peroxisome proliferator activated receptor (PPAR) modulator and an polymeric nanocarrier component, wherein the polymeric nanocarrier component is capable of solubilising the PPAR modulator in an aqueous medium and, wherein in the polymeric nanocarrier component is a micelle forming non-ionic surfactant. Uses of the same in therapy are also provided.

LIPID COMPOSITION AND METHOD OF DELIVERING THERAPEUTIC AGENT

Resumen de: AU2023365462A1

It is an object of the present invention to provide a lipid composition capable of delivering a nucleic acid such as RNA to a hematopoietic stem/progenitor cell or mesenchymal stem cells, and a method of delivering a therapeutic agent to a cell using the lipid composition. The present invention provides a lipid composition comprising (A) a therapeutic agent and (B) a lipid nanoparticle conjugated to a targeting molecule, wherein the lipid nanoparticle comprises an ionizable lipid, and the targeting molecule specifically binds to a marker of hematopoietic stem / progenitor cells or mesenchymal stem cells.

NOVEL IONIZABLE LIPIDS

Resumen de: AU2023361218A1

The present invention relates to compounds of formula (I). The invention also extends to micro- or nanoparticles comprising a compound of formula (I). For instance, compounds of formula (I) can be used to produce stable lipid nanoparticles (LNPs). The LNPs have high encapsulation efficiency and can be used to deliver a therapeuticor prophylactic agent to a patient.

MODIFIED OLIGONUCLEOTIDES

Resumen de: AU2023360051A1

The invention relates to oligonucleotides that inhibit Toll-Like Receptor 7 (TLR7) and/or Toll-Like Receptor 8 (TLR8), or potentiate TLR8, and uses thereof.

NOVEL SECRETORY SIGNAL PEPTIDES

Resumen de: AU2023347284A1

Provided here are novel engineered and isolated signal peptide sequences and compositions comprising these. Also provided are compositions and methods of using these signal peptides to enable secretion of heterologous polypeptides for therapeutic, diagnostic, and commercial value.

SUGAR-CONJUGATED LIPID NANOPARTICLES AND METHODS OF USE THEREFOR

Resumen de: WO2025091046A1

Provided are compositions that include compositions of galactosyl -conjugated lipid nanoparticles (LNPs) encapsulating one or more active agents. In some embodiments, the galactosyl- conjugated LNPs have a lipid component having D-Lin~MC3-DMA, ALC-0315 and. SM-102, cholesterol, DSPC and DOPE, and DMG-2000-PEG. In some embodiments, the GalNAc-conjugated LNP has one or more galactosyl moieties bioconjugated to cholesterol present with a lipid component of the GalNAc -conjugated LNP. Also provided are methods for treating and/or preventing diseases, disorders, and/or conditions associated, with undesirable PCSK9 gene expression, optionally a cardiovascular disease, disorder, or condition, including but not limited, to atherosclerosis and/or thrombosis, and sepsis, septic shock, cytokine storm, or sequelae thereof.

A COMPOUND FOR PREPARING LIPID NANOPARTICLES ENCAPSULATING AN AGENT, NANOPARTICLE COMPOSITION COMPRISING SAID COMPOUND, AND RELATED METHODS THEREOF

Resumen de: WO2025090023A1

There is provided a compound comprising a structure represented by general formula (1) or an ionized form thereof for preparing lipid nanoparticles encapsulating a therapeutic, prophylactic and/or biological agent: wherein R5 and each R6 are independently H, optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl; R3, and each R7 are independently optionally substituted alkylene, optionally substituted alkenylene, or optionally substituted alkynylene; n is from 0 to 100; l and m are each independently 0 or 1; each A is independently selected from H, aliphatic alcohol, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, an epoxy ring- opening product and/or derivatives thereof; and B is R1R2N- or R23O- where R1 and R2 are each independently H, or a hydrophobic tail with the proviso that both of R1 and R2 are not H at the same 116 time; and where R23 is optionally substituted alkyl, optionally substituted alkenyl, or optionally substituted alkynyl.

BISPECIFIC STEALTH LIPID NANOPARTICLE COMPOSITIONS FOR CELL TARGETING

Resumen de: WO2025090417A1

The present disclosure provides bispecific stealth lipid nanoparticle (LNP) compositions engineered to target specific tissues or cell-types, e.g., hematopoietic stem cells, to modify the cells with therapeutic nucleic acid encapsulated in the LNP. The present disclosure also provides compositions and methods of making the LNPs and treatment using the same.

NOVEL POLYGLYCEROL-CONJUGATED LIPIDS AND LIPID NANOPARTICLE COMPOSITIONS COMPRISING THE SAME

Resumen de: WO2025090663A1

The present disclosure provides novel polymer-conjugated lipids conjugated to a polyglycerol or a polyglycerol derivative. The present disclosure also provides lipid nanoparticles (LNPs) formulation using the polymer-conjugated lipids and methods of treating a disease by administering the LNP formulations, including multiple doses of the LNP formulations.

METHOD OF USE OF MESOPOROUS SILICA RODS FOR TREATING CANCER

Nº publicación: WO2025090756A2 01/05/2025

Solicitante:

ATTIVARE THERAPEUTICS INC [US]
ATTIVARE THERAPEUTICS INC

Resumen de: WO2025090756A2

Embodiments of the invention include methods of treating conditions that are ameliorated by stimulating an immune response. In aspects, the methods include subcutaneous injection of mesoporous silica rods into a subject or patient. The mesoporous silica rods can include a cytokine (e.g., IL-2 or IL-12) and/or an adjuvant. The mesoporous silica structures can induce an innate systemic immune response to treat cancer, infection and other ailments. Embodiments also include methods of producing mesoporous silica rods.